Essadi Ismail, Sbitti Yassir, Fetohi Mohamed, Slimani Khaoula Alaoui, Essadi Meryam, Tazi Elmehdi, Ichou Mohamed, Errihani Hassan
Department of Medical Oncology at the Military Hospital Mohamed V, Rabat, Morocco.
National Institute of Statistics and Applied Economics (INSEA), Rabat, Morocco.
Gastroenterology Res. 2011 Jun;4(3):122-124. doi: 10.4021/gr317e. Epub 2011 May 20.
The management of hepatic metastases from colorectal cancer can be understood only as part of a multidisciplinary strategy. Progress experienced by medical treatment, surgical techniques and ways of imaging, has improved the prognosis of patients with liver metastases of colorectal cancers. This work displays the experience of Medical Oncology unit at the Military training hospital in Rabat.
From January 2007 to December 2009, 60 patients with liver metastases from colorectal cancer, synchronous or metachronous were supported in the Medical Oncology unit at the Military training hospital in Rabat.
Liver metastases were synchronous in 41 (68%) patients and metachronous in 19 (32%). Patients were classified into 3 categories according to their resectability: 14 (22%) were resectable at the outset, 28 (47%) were unresectable and 18 (31%) were considered uncertain resectability. Thirty-five patients (58%) received neoadjuvant chemotherapy before surgical gesture, 25 (42%) received chemotherapy after resection of primary tumor. This chemotherapy enabled the resection of liver metastases in 5 patients initially deemed uncertain resectability. The average objective responses to chemotherapy were in the range of 59% with 4 complete responses and one confirmed histologically. Twenty-three patients (38%) underwent surgery including 15 liver resections with R0 (25%). The median progression-free survival in this series was 15.5 months. Some minor side effects were noted, which have not entered the prognosis of patients.
Hepatic resection remains the only potentially curative treatment of liver metastases of colorectal cancers. Perioperative chemotherapy is a promising standard, which has improved the prognosis of patients historically associated with a poor prognosis.
结直肠癌肝转移的管理只能作为多学科策略的一部分来理解。医学治疗、手术技术和成像方式的进步改善了结直肠癌肝转移患者的预后。本文展示了拉巴特军事训练医院肿瘤内科的经验。
2007年1月至2009年12月,拉巴特军事训练医院肿瘤内科为60例结直肠癌肝转移患者(包括同时性或异时性肝转移)提供了支持。
41例(68%)患者为同时性肝转移,19例(32%)为异时性肝转移。根据可切除性将患者分为3类:14例(22%)一开始即可切除,28例(47%)不可切除,18例(31%)可切除性不确定。35例患者(58%)在手术前接受了新辅助化疗,25例(42%)在原发肿瘤切除后接受了化疗。这种化疗使5例最初被认为可切除性不确定的患者能够切除肝转移灶。化疗的平均客观缓解率为59%,有4例完全缓解,1例经组织学证实。23例患者(38%)接受了手术,其中15例进行了R0肝切除术(25%)。该系列患者的无进展生存期中位数为15.5个月。观察到一些轻微的副作用,但这些并未影响患者的预后。
肝切除术仍然是结直肠癌肝转移唯一可能治愈的治疗方法。围手术期化疗是一种有前景的标准治疗方法,改善了历史上预后较差患者的预后。